MATCH Treatment Subprotocol N: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients With Tumors With PTEN Mutation or Deletion, With PTEN Expression on IHC
Latest Information Update: 01 Nov 2024
Price :
$35 *
At a glance
- Drugs GSK 2636771 (Primary)
- Indications Cancer; Lymphoma; Multiple myeloma
- Focus Therapeutic Use
- Acronyms MATCH-Subprotocol N
- 29 Oct 2024 Planned End Date changed from 30 Nov 2024 to 30 Nov 2025.
- 29 Oct 2024 Planned primary completion date changed from 30 Nov 2024 to 30 Nov 2025.
- 13 Dec 2023 Planned End Date changed from 30 Nov 2023 to 30 Nov 2024.